| Bioactivity | Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for treating type 2 diabetes. |
| Invitro | Luseogliflozin (TS-071, 3p) is a potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM); Luseogliflozin has the protential for treating type 2 diabetes[1]. |
| In Vivo | Luseogliflozin (1 mg/kg, p.o.) exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in rats and dogs[1]. |
| Name | Luseogliflozin |
| CAS | 898537-18-3 |
| Formula | C23H30O6S |
| Molar Mass | 434.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kakinuma H, et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010 Apr 22;53(8):3247-61. |
Luseogliflozin
CAS: 898537-18-3 F: C23H30O6S W: 434.55
Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor,
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.